Category Archives: Public Policy

Latest From Public Policy

Biotech Patenting and Tech Transfer at 2011 BIO International Convention

BIO11_ConvLogo_L_RGB

The Biotech Patenting and Tech Transfer track has a lot to offer 2011 BIO International Convention Attendees.  High level speakers include White House Intellectual Property Enforcement Coordinator Victoria Espinel, European Patent Office Director of Biotechnology Sjoerd Hoekstra, retired Chief Judge of the U.S. Court of Appeals for the Federal Circuit Paul Michel, and former Solicitors General Seth Waxman and Paul Clement to name a few.                 I am particularly excited about the breadth of the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , ,

House Patent Reform Bill, HR 1249, still has the Administration’s and BIO’s support

patent reform june 22 2011

The White House, Office of Management and Budget, Office of Science and Technology Policy, and the United States Patent and Trademark Office have come out in support of HR 1249 and the Manager’s Amendment to the bill.  The only caveat mentioned is that “final legislative action [should] ensure that the US Patent and Trademark Office’s (USPTO’s) fee collections are made fully available to support the nation’s patent and trademark system.” BIO also has come out in Read More >

Patently BIOtech  |  3 Comments  |  Email This Post
Tags: , , , , , ,

‘Gene Patents’ Stifle Research?

'Gene Patents' Stifle Research?

The Federal Trade Commission has noted that “concern previously centered on the belief that biotechnology patent protection was too strong” and “would actually obstruct commercialization on new products, thereby hindering follow-on innovation.  This problem has yet to materialize.  The reasons for this are numerous and are often straightforward matters of basic economics. In addition to licensing being widely available, researchers make use of a variety [of] strategies to develop working solutions to the problem of Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Intellectual Property problems for personalized medicine

Amid growing interest in personalized medicine that stands to provide patients with better care at reduced costs, legal battles over gene patents ensue, threatening the viability of widespread implementation. On this topic authors Jennifer Gordon, Steve Lendaris and Anna Volftsun (layers at Baker Botts LLP) wrote a very interesting opinion article for The Scientist on the topic. They also examine the barriers to personalized medicine, including a pending decision in the Myriad Genetics case, and Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Translational Research Forum at BIO International Convention

3636396892_0eec72e0a6

BIO is hosting a Translation Research Forum at the BIO International Convention.  NIH Director Collins keynotes an event that will explore how private, public and academic sectors can leverage meaningful partnerships, highlight emerging best practices, explore risk-sharing at the clinical research stage, and explore ways to bridge the gap in funding and know-how necessary to take university research to the next level. Read the Press Release for more information about panels and speakers. For registration, conference Read More >

Patently BIOtech  |  2 Comments  |  Email This Post
Tags: , , , , , , ,